ALKSClinical Trials•prnewswire•
Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025
Sentiment:Positive (75)
Summary
– Results From Vibrance-1 to Be Shared in Three Oral Presentations, Including Primary and Secondary Efficacy and Safety Measures, and Exploratory Patient-Reported Outcomes Related to Disease Severity, Fatigue and Cognition – – Company to Host Investor Webcast on Monday, Sept. 8 at 8:00...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 25, 2025 by prnewswire